Melius Pharma

Executive Summary

Melius Pharma AB is a Swedish clinical-stage pharmaceutical company founded in 2021, dedicated to developing novel treatments for severe diseases with high unmet medical needs. The company's lead program, ME-015, is an oral therapy targeting chronic cough in Idiopathic Pulmonary Fibrosis (IPF), a debilitating condition with no approved treatments specifically for cough. Melius has strategically focused on de-risking clinical development by leveraging established biomarkers and patient-reported outcomes, positioning itself to address a significant market gap. With ME-015 advancing through Phase 2/3 trials, the company is poised to generate pivotal data that could support regulatory filings and attract strategic partnerships. The company's approach centers on repurposing known mechanisms with a strong safety profile, potentially accelerating time-to-market and reducing development costs. While still in early stages, Melius Pharma benefits from a lean operational model and a clear focus on a specific, high-need indication. Success in chronic cough for IPF could not only improve quality of life for patients but also establish a platform for expanding into other pulmonary conditions. Given the limited competition in this niche, Melius represents a speculative but potentially high-reward opportunity for investors seeking exposure to orphan drug development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 top-line data readout for ME-015 in chronic cough due to IPF45% success
• Q3 2026Regulatory guidance meeting (FDA/EMA) for pivotal trial design70% success
• TBDLicensing or co-development partnership for ME-01530% success